Transplantation of Mesenchymal Stem Cells Attenuates Pulmonary Hypertension by Normalizing the EndMT.
For decades, stem cell therapies for pulmonary hypertension (PH) have progressed from laboratory hypothesis to clinical practice. Promising preclinical investigations have laid both a theoretical and practical foundation for clinical application of MSC for PH therapy. However, the underlying mechanisms are still poorly understood. To study the effects and mechanisms of mesenchymal stem cells (MSC) on the treatment of PH. For in vivo experiments, the transplanted GFP+ MSC were traced at different time points in the lung tissue of chronic hypoxia-induced pulmonary hypertension (CHPH) rat model. The effects of MSC on PH pathogenesis were evaluated in both CHPH and SuHx-PH models. For in vitro experiments, primary pulmonary microvascular endothelial cells (PMEC) were cultured and treated with the MSC conditioned medium (MSC-CM). The specific markers of EndMT and cell migration property were measured. MSC decreased pulmonary arterial pressure and ameliorated the collagen deposition, reduced the thickening and muscularization in both CHPH and SuHx-PH rat models. Then, MSC significantly attenuated the hypoxia-induced EndMT in both the lungs of PH models and primary cultured rat PMEC, reflected by increased mesenchymal cell markers (Fibronectin 1 and vimentin) and decreased endothelial cell markers (VE-cadherin and PECAM-1). Moreover, MSC also markedly inhibited the protein expression and degradation of HIF2α, which is known to trigger EndMT progression. Our data suggested MSC successfully prevents PH by ameliorating pulmonary vascular remodeling, inflammation, and EndMT. Transplantation of MSC could be a potential powerful therapeutic approach against PH.